[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-462082-105":59,"doc-detail-462082-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","in-vivo-target-engagement-assessment-of-nintedanib-in-a-double-hit-bleomycin-lung-fibrosis-rat-model","In Vivo Target Engagement Assessment of Nintedanib in a Double-Hit Bleomycin Lung Fibrosis Rat Model","","Nintedanib is an anti-fibrotic, multi-kinase inhibitor approved for idiopathic pulmonary fibrosis (IPF), proposed to act mainly through inhibition of VEGF, PDGF, and FGF receptor kinases. The study aimed to identify tissue and/or circulating biomarkers that demonstrate Nintedanib target engagement and support in vivo pharmacodynamic activity. In four independent rat experiments using bleomycin-induced lung fibrosis, Nintedanib reduced lung weight, fibrotic markers, and fibrotic areas, with altered VEGF, FGF2, proteomic receptor tyrosine kinase signaling, and pharmacokinetic distribution consistent with clinical data.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/in-vivo-target-engagement-assessment-of-nintedanib-in-a-double-hit-bleomycin-lung-fibrosis-rat-model/462082/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/in-vivo-target-engagement-assessment-of-nintedanib-in-a-double-hit-bleomycin-lung-fibrosis-rat-model/462082.png","ImageObject",300,407,{"name":92,"@type":93},"Miles","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-30",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main objective of this study?","Question",{"text":112,"@type":113},"To identify potential tissue and/or circulating biomarkers that demonstrate Nintedanib target engagement and support its in vivo pharmacodynamic activity.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was Nintedanib administered in the rat lung fibrosis experiments?",{"text":117,"@type":113},"Rats received Nintedanib (oral, 100 mg/kg/day) starting on day 7 after bleomycin and continuing for 3 weeks.",{"name":119,"@type":110,"acceptedAnswer":120},"Which biomarker changes were observed in Nintedanib-treated animals?",{"text":121,"@type":113},"Nintedanib increased VEGF levels in plasma and lung (≥3-fold, p \u003C 0.05) and decreased FGF2 levels in lung homogenates, alongside reduced fibrotic markers and areas.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},462082,1790794541,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},13056703019404,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Article  \nIn Vivo Target Engagement Assessment of Nintedanib in a Double-Hit Bleomycin Lung Fibrosis Rat Model  \nVanessa Pitozzi 1, *,†, Paola Lorenza Caruso 1,†, Silvia Pontis 1, Barbara Pioselli 1, Francesca Ruscitti 1, Maria Gloria Pittelli 1, Costanza A. M. Lagrasta 2, Federico Quaini 2, Antonella Maria Nogara 2, Giancarlo Aquino 1, Roberta Volta 1, Maria Laura Faietti 1, Martina Bonatti 3, Paolo Spagnolo 4 and Marcello Trevisani 1  \nAcademic Editor: Galina  \nS. Bogatkevich  \nReceived: 11 November 2025  \nRevised: 14 December 2025  \nAccepted: 18 December 2025  \nPublished: 20 December 2025  \nCopyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Chiesi Farmaceutici S.p.A., Global Research and Preclinical Development Area, Largo Belloli, 11/A,  \n43122 Parma, Italy; [s.pontis@chiesi.com](s.pontis@chiesi.com) (S.P.); [b.pioselli@chiesi.com](b.pioselli@chiesi.com) (B.P.); [f.ruscitti@chiesi.com](f.ruscitti@chiesi.com) (F.R.); [m.pittelli@chiesi.com](m.pittelli@chiesi.com) (M.G.P.); [g.aquino@chiesi.com](g.aquino@chiesi.com) (G.A.); [r.volta@chiesi.com](r.volta@chiesi.com) (R.V.); [ml.faietti@chiesi.com](ml.faietti@chiesi.com) (M.L.F.); [m.trevisani@chiesi.com](m.trevisani@chiesi.com) (M.T.)  \n2 Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy; [costanzaannamaria.lagrasta@unipr.it](costanzaannamaria.lagrasta@unipr.it) (C.A.M.L.); [federico.quaini@unipr.it](federico.quaini@unipr.it) (F.Q.); [antonellamaria.nogara@unipr.it](antonellamaria.nogara@unipr.it) (A.M.N.)  \n3 Respiratory Medicine Unit, Department of Medicine & Center for Molecular Medicine, Karolinska Institute, 17176 Stockholm, Sweden; [martina.bonatti@ki.se](martina.bonatti@ki.se)  \n4 Respiratory Disease Unit, Department of Cardiac Thoracic, Vascular Sciences and Public Health, University of Padova, 35128 Padova, Italy; [paolo.spagnolo@unipd.it](paolo.spagnolo@unipd.it)  \n* [Correspondence: v.pitozzi@chiesi.com](Correspondence: v.pitozzi@chiesi.com)  \n† These authors contributed equally to this work.  \nAbstract  \nNintedanib is an anti-fibrotic medication endowed with a multi-kinase inhibitor profile and approved for the treatment of Idiopathic Pulmonary Fibrosis (IPF) . Nintedanib is believed to inhibit mainly Vascular Endothelial Growth Factor (VEGF), Platelet-Derived Growth Factor (PDGF), and Fibroblast Growth Factor (FGF) receptor kinases. The main objective was to identify potential tissue and/or circulating biomarkers to demonstrate Nintedanib’starget engagement and support its in vivo pharmacodynamic activity, consistent with its proposed mechanism(s) of action. In four independent experiments of bleomycin (BLM)-induced lung fibrosis model in rats, animals received Nintedanib (oral, 100 mg/kg/day) from day 7 post-BLM for 3 weeks. As expected, Nintedanib significantly reduced lung weight, the levels of lung fibrotic markers, and fibrotic areas. Moreover, Nintedanib-treated animals expressed lower levels of FGF2 in lung homogenates and higher plasma and lung levels of VEGF (≥3-fold, p \u003C 0.05) compared to control animals. Lung proteomic analysis revealed the inhibition of receptor tyrosine kinases signaling in Nintedanib-treated animals. Circulating and lung levels of Nintedanib confirmed an optimal tissue distribution in the rat, consistent with the data reported for humans. Although VEGF ligand levels are elevated in the lungs of Nintedanib-treated animals, the VEGF signaling pathway remained functionally downregulated, strongly suggesting compensatory VEGF feedback delivery to its receptor blockade by Nintedanib. In summary, based on the present experimental findings in rats and supporting clinical preliminary evidence, increased VEGF levels can be reasonably considered an indicator of target engagement for Nintedanib and potentially for other VEGF modulators.  \nKeywords: Nintedanib; idio","cbCaiizNJxUjiK36","https://ap.wps.com/l/cbCaiizNJxUjiK36","pdf",2277915,17,"English","# Abstract\n# Introduction","[{\"question\":\"What is the main objective of this study?\",\"answer\":\"To identify potential tissue and/or circulating biomarkers that demonstrate Nintedanib target engagement and support its in vivo pharmacodynamic activity.\"},{\"question\":\"How was Nintedanib administered in the rat lung fibrosis experiments?\",\"answer\":\"Rats received Nintedanib (oral, 100 mg/kg/day) starting on day 7 after bleomycin and continuing for 3 weeks.\"},{\"question\":\"Which biomarker changes were observed in Nintedanib-treated animals?\",\"answer\":\"Nintedanib increased VEGF levels in plasma and lung (≥3-fold, p \\u003c 0.05) and decreased FGF2 levels in lung homogenates, alongside reduced fibrotic markers and areas.\"}]","In Vivo Target Engagement Assessment of Nintedanib in a Double-Hit Bleomycin Lung Fibrosis Rat Model | PDF",1790763210,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/3af1a26ed771dcbd3ea77a07ac36ca97.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/2408f033a85c691392e2daca983a42ff.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/9ccceadf168832714c23f7ba3ace3506.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/95e68602e85f0fd2b149116fa180cbb3.webp",980,1385]